Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 5, 2010, Pages 515-523

  Farr, Sherry L ^a   Nelson, Julie A E ^b,c   Ng'Ombe, Thokozani J ^d   Kourtis, Athena P ^a   Chasela, Charles ^d   Johnson, Jeffrey A ^e   Kashuba, Angela D M ^b   Tegha, Gerald L ^d   Wiener, Jeffrey ^a   Eron, Joseph J ^c   Banda, Harriet N ^c   Mpaso, Mwanangwa ^d   Lipscomb, Jonathan ^e   Matiki, Chrissie ^d   Fiscus, Susan A ^b,c   Jamieson, Denise J ^a   Van Der Horst, Charles ^c  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

drug resistance; HIV; nevirapine; pregnancy; zidovudine and lamivudine

Indexed keywords

LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BREAST MILK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALAWI; NONHUMAN; PRIORITY JOURNAL; PUERPERIUM; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; LONGITUDINAL STUDIES; MALAWI; NEVIRAPINE; PLASMA; POLYMERASE CHAIN REACTION; POSTPARTUM PERIOD; PREGNANCY; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; YOUNG ADULT; ZIDOVUDINE;

EID: 77954966735     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e3a70e     Document Type: Article

References (31)

1. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala Uganda: HIVNET 012 randomised trial. Lancet. 1999. 354. 795-802.
2. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-868.
3. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis. 2005;192:30-36.
4. Eshleman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS. 2005;19:2167-2169.
5. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis. 2007;195:711-715.
6. Arrive E, Chaix ML, Nerrienet E, et al. The TEmAA ANRS 12109 Phase II Trial, Step 1: tolerance and viral resistance after single-dose nevirapine and short-course of tenofovir disoproxil fumarate and emtricitabine to prevent mother-to-child transmission of HIV-1. Presented at: 15th Conference on Retrovirals and Oppotunistic Infections; Boston, MA; February 4, 2008. Abstract.
7. Wind-Rotolo M, Durand C, Cranmer L, et al. Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis. 2009;199: 1301-1309.
8. Chi BH, Sinkala M, Stringer EM, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS. 2007;21:957-964.
9. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007; 356:135-147.
10. Bulletin: DSMB Finds Ritonavir-boosted Lopinavir Superior to Nevir-apine in HIV-positive Women Who Previously Took Single-Dose Nevirapine. National Institute of Allergy and Infectious Disease, National Institutes of Health; October 1. 2008. Electronic citation.
11. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229-240.
12. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. 4-year clinical and therapeutic consequences of intra-partum sungle-dose nevirapine fo rthe prevention of perinatal HIV in women who subsequently initiated a nevirapine-based ART. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; February 10, 2009. Abstract.
13. Lockman S, Smeaton L, Ogwu A, et al. Long-term maternal and pediatric virologic outcomes on nevirapine-based HAART following receipt of peripartum single-dose nevirapine or placebo, Botswana. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; February 11, 2009. Abstract.
14. Moses A, Zimba C, Kamanga E, et al. Prevention of mother-to-child transmission: program changes and the effect on uptake of the HIVNET 012 regimen in Malawi. AIDS. 2008;22:83-87.
15. Lowrance DW, Makombe S, Harries AD, et al. A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004-2006. J Acquir Immune Defic Syndr. 2008;49:287-293.
16. Van der Horst C, Chasela C, Ahmed Y, et al. Modifications of a large HIV prevention clinical trial to fit changing realities: A case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi. Contemp Clin Trials. 2009;30:24-33.
17. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005;192:16-23.
18. Johnson JA, Li JF, Wei X, et al. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS ONE. 2007;2:e638.
19. Rezk NL, Tidwell RR, Kashuba AD. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;791:137-147.
20. Rezk NL, bdel-Megeed MF, Kashuba AD. Development of a highly efficient extraction technique and specific multiplex assay for measuring antiretroviral drug concentrations in breast milk. Ther Drug Monit. 2007; 29:429-436.
21. Holland DT, DiFrancesco R, Connor JD, et al. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit. 2006; 28:367-374.
22. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-706.
23. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of Mother-to-Child HIV Transmission: a Randomized Clinical Trial. PLoS Med. 2009; 6:e1000172.
24. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951-1957.
25. Kassaye S, Lee E, Kantor R, et al. Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis. AIDS Res Hum Retroviruses. 2007;23: 1055-1061.
26. Lee EJ, Kantor R, Zijenah L, et al. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis. 2005;192:1260-1264.
27. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus Abidjan, Cote d'Ivoire. J Infect Dis. 2006;193:482-487.
28. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet. 2007; 370:1698-1705.
29. Lallemant M, Jourdain G, Ngo-Giang-Huong N, et al. Efficacy and safety of 1-moth post-partum zidovudine and didanosine to prevent HIV-1 nevirapine resistance mutations following intrapartum single-dose nevirapine. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; February 10, 2009. Abstract.
30. Van Dyke R, Jourdain G, Shapiro D, et al. A Phase II Study of the incidence of nevirapine resistance mutations in HIV-infected Thai women receiving a single intrapartum dose of NVP followed by a postpartum tail of ZDV/ddl or ZDV/ddl/LPV/r: IMPAACT P1032. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; February 10, 2009. Abstract.
31. Palumbo P, Violari A, Lindsay J, et al. Nevirapine (NVP) vs lopinavir-ritonavir (LPV/r)-based antiretroviral therapy (ART) in single dose nevirapine (sdNVP)-exposed HIV-infected infants: preliminary results from the IMPAACT P1060 trial. Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; July 19-22, 2009. Abstract.